UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 22, 2004 |
Date of Report (Date of earliest |
NEORX CORPORATION
(Exact Name of Registrant as Specified in Charter)
Washington |
| 0-16614 |
| 91-1261311 |
(State or Other Jurisdiction of Incorporation) |
| (Commission File No.) |
| (IRS Employer Identification No.) |
300 Elliott Avenue West, Suite 500, Seattle, Washington |
| 98119-4114 |
(Address of principal executive offices) |
| (Zip Code) |
(206) 281-7001 |
(Registrant’s telephone number, including area code) |
On March 22, 2004, NeoRx announced that it had executed an agreement with The University of Missouri-Columbia Research Reactor Center (MURR), under which MURR will manufacture and supply to NeoRx the radioisotope holmium-166 for NeoRx’s phase III clinical trial of STR™ (Skeletal Targeted Radiotherapy). See press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press release dated March 22, 2004, announcing execution of an agreement with The University of Missouri-Columbia Research Reactor Center |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| NEORX CORPORATION | |||
|
|
|
| ||
|
|
|
| ||
Dated March 24, 2004 |
| By | /s/ | MELINDA G. KILE |
|
|
|
| Melinda G. Kile | ||
|
|
| Vice President, Finance | ||
3
Exhibit No. |
| Description |
|
|
|
99.1 |
| Press release dated March 22, 2004, announcing execution of an agreement with The University of Missouri-Columbia Research Reactor Center |
4
